Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products and the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical st
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Balaton, MN (PRWEB) April 27, 2015 ... into an agreement with Texas A&M University for the ... referred to as super-intensive raceway systems. The license agreement ... Dr. Addison Lawrence, extends to countries such as China, ... United Kingdom. , “We have had inquires from ...
(Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
(Date:4/27/2015)... -- Together with its customers, Elekta raised EUR 30,575 (USD ... Barcelona . The funds will be donated to ... improve cancer care, specifically radiation oncology care, around the ... should be denied potentially life-saving treatment simply because the ... and clinics around the world to take care of ...
(Date:4/27/2015)... 2015 Elsevier , a world-leading ... and Qatar University Research Office   have announced the winners ... The awards ceremony, held last week at Qatar ... by more than 40 guests representing Qatar,s ... Professor Sheikha Abdulla Al-Misnad , President of ...
Breaking Biology Technology:tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 5
... Nov. 29 As part of an ongoing ... maximize commercial,impact of their products, Premier Research Group ... industry-leading expertise in its core,service areas into a ... expertise within the group closely matches Premier Research,s ...
... Multi-stakeholder initiative will use health information technology ... safety efforts across,the U.S., WASHINGTON, Nov. ... announced today the formation of an innovative,research ... patients. The eHI,Connecting Communities for Drug Safety ...
... Prometheus Laboratories Inc., a,specialty pharmaceutical company ... exclusive license agreement to develop and commercialize ... North America from,Alizyme Therapeutics Limited, a wholly ... unique competitive profile based on Alizyme,s proprietary,COLAL(R) ...
Cached Biology Technology:Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research 2eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 2eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 3eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 4eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 5eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 6Prometheus Licenses COLAL-PRED(R) From Alizyme 2Prometheus Licenses COLAL-PRED(R) From Alizyme 3Prometheus Licenses COLAL-PRED(R) From Alizyme 4
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... of Toronto and the Swiss Federal Institute of Technology ... exotic plants will likely eliminate native plants growing in ... A study published in Proceedings of the National ... that invasive plants are not problematic are often based ...
... January 2013) The microbial communities that reside in the ... are an expanding area of research full of exciting discoveries ... on the most recent advances in the field, scientists and ... For Health World Summit, which is hosted this year by ...
... changed diabetes from a death sentence to a chronic ... Case Western Reserve University School of Medicine announced a ... lives of people managing diabetes. After decades of ... international group of scientists finally found a definitive answer: ...
Cached Biology News:Invading species can extinguish native plants despite recent reports 2After decades of research, scientists unlock how insulin interacts with cells 2After decades of research, scientists unlock how insulin interacts with cells 3
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: